Comparing of resTORbio Inc. (TORC) and KalVista Pharmaceuticals Inc. (NASDAQ:KALV)

Both resTORbio Inc. (NASDAQ:TORC) and KalVista Pharmaceuticals Inc. (NASDAQ:KALV) are Biotechnology companies, competing one another. We will compare their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
resTORbio Inc. N/A 0.00 37.61M -2.06 0.00
KalVista Pharmaceuticals Inc. 18.04M 25.02 12.95M -1.23 0.00

Demonstrates resTORbio Inc. and KalVista Pharmaceuticals Inc. earnings per share (EPS), gross revenue and valuation.


Table 2 shows the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
resTORbio Inc. 0.00% -67.6% -50.1%
KalVista Pharmaceuticals Inc. -71.78% -30.1% -17.9%


The current Quick Ratio of resTORbio Inc. is 14.5 while its Current Ratio is 14.5. Meanwhile, KalVista Pharmaceuticals Inc. has a Current Ratio of 6.2 while its Quick Ratio is 6.2. resTORbio Inc. is better positioned to pay off its short-term and long-term debts than KalVista Pharmaceuticals Inc.

Analyst Recommendations

Ratings and Recommendations for resTORbio Inc. and KalVista Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
resTORbio Inc. 0 0 0 0.00
KalVista Pharmaceuticals Inc. 0 0 1 3.00

Competitively KalVista Pharmaceuticals Inc. has an average target price of $35, with potential upside of 33.74%.

Institutional and Insider Ownership

resTORbio Inc. and KalVista Pharmaceuticals Inc. has shares owned by institutional investors as follows: 43.7% and 82.2%. Insiders owned 5.7% of resTORbio Inc. shares. Comparatively, insiders own roughly 2.9% of KalVista Pharmaceuticals Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
resTORbio Inc. 9.49% -1.24% -34.65% -19.47% -52.26% 1.74%
KalVista Pharmaceuticals Inc. 2.29% 21.99% -0.57% 39.88% 120.29% 15.44%

For the past year resTORbio Inc. was less bullish than KalVista Pharmaceuticals Inc.


KalVista Pharmaceuticals Inc. beats resTORbio Inc. on 8 of the 10 factors.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The companyÂ’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products under development include KVD818, an orally delivered molecule that is in Phase I clinical trial for the treatment of HAE; KVD001, an intravitreally administered plasma kallikrein inhibitor that has completed a Phase I clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein that is in preclinical safety studies for use against human proteases related to plasma kallikrein. The company is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.